From CEO interview last week that they are investigating the drug for kidney disease indication. TRPC 3,6 like the brain and heart also all over the kidney. NYR-BO3 will have an added indication in reducing necrosis of the kidney in the coming period ahead. Ischemic Kidney injury is a 11 billion dollar market. Bought more again today and this rubbish 19 million market cap will become a 100 million dollar plus market cap like its peers but will have cardiovascular and kidney disease indications
Ann: Change of Registered Office and Principal Place of Business, page-21
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
22.0¢ |
Change
-0.025(10.2%) |
Mkt cap ! $46.40M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 25.0¢ | 22.0¢ | $256.0K | 1.085M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 67420 | 22.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 25083 | 2 |
View Market Depth
| Last trade - 16.10pm 24/06/2025 (20 minute delay) ? |
| NYR (ASX) Chart |